Cubist does a double whammy - Acquires Optimer and Trius

Earlier this week, Cubist announced that it would be buying two other antibiotics developers, Trius Therapeutics and Optimer Pharmaceuticals. Cubist is paying an initial $707mm in cash for Trius, with an additional $111mm in contingent value rights (CVRs) - approximately $2.00 per share more - payable in the event that Trius's lead drug candidate, tedizolid phosphate, generates over $135mm in sales in 2016. For Optimer, Cubist is paying an initial $535mm in cash, with additional CVRs amounting to $266mm payable if Optimer's main marketed product, fidaxomicin, generates over $300mm in cumulative net sales between end-July 2013 and end-2015.












Enter your email address: Delivered by FeedBurner

Cubist acquires rights to ceftolozane from Astellas

Cubist Pharmaceuticals has acquired the remaining rights to ceftolozane for the treatment of  urinary tract infections, in certain Asia-Pacific and Middle East territories from Astellas Pharma Inc. Cubist will now own worldwide rights to develop, manufacture and commercialize the drug, which in combination with tazobactam is currently being studied in two third-round trials as a potential first-line intravenous therapy for treating complicated intra-abdominal infections and urinary tract infections.